0001140361-24-009029.txt : 20240222
0001140361-24-009029.hdr.sgml : 20240222
20240222160645
ACCESSION NUMBER: 0001140361-24-009029
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240220
FILED AS OF DATE: 20240222
DATE AS OF CHANGE: 20240222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SIEGAL JONATHAN
CENTRAL INDEX KEY: 0001916145
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 24664718
MAIL ADDRESS:
STREET 1: C/O VERICEL CORPORATION
STREET 2: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
form4.xml
FORM 4
X0508
4
2024-02-20
0000887359
Vericel Corp
VCEL
0001916145
SIEGAL JONATHAN
64 SIDNEY STREET
CAMBRIDGE
MA
02139
true
Principal Accounting Officer
false
Common Stock
2024-02-20
4
M
0
2500
0
A
3900
D
Common Stock
2024-02-20
4
F
0
1117
49.5
D
2783
D
Common Stock
2024-02-20
4
M
0
420
0
A
3203
D
Common Stock
2024-02-20
4
F
0
169
49.5
D
3034
D
Restricted Stock Unit
2024-02-20
4
M
0
2500
A
Common Stock
2500
7500
D
Restricted Stock Unit
2024-02-20
4
M
0
420
A
Common Stock
420
840
D
The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively.
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2025, and February 18, 2026, respectively.
Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
No expiration date for this type of award.
The Fair Market Value of the vested derivative securities is $49.50 per share.
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Siegal
2024-02-22